



A



B



JUN knock-down not PKC-alpha knockdown is effective co-treatment option. Effect on cell viability of vemurafenib and JUN or PKC-alpha siRNA knockdown co-treatment for parental (M238P) and vemurafenib co-treated M238P cells (M238P+vem). Cell viability was assessed after 3 days by a MTS assay. (A) JUN knockdown. (B) PKC-alpha knockdown